Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.

[1]  P. Marzullo,et al.  Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). , 2000, The Journal of clinical endocrinology and metabolism.

[2]  P. Chanson,et al.  Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. , 2000, European journal of endocrinology.

[3]  F. Casanueva,et al.  Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.

[4]  G. Gussoni,et al.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  I. Lancranjan,et al.  Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. , 1995, The Journal of clinical endocrinology and metabolism.

[6]  W. Young,et al.  Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[7]  P. Caron,et al.  Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). , 1995, European journal of endocrinology.

[8]  P. Chanson,et al.  Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. , 1994, The Journal of clinical endocrinology and metabolism.

[9]  J. Kuhn,et al.  Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. , 1993, The Journal of clinical endocrinology and metabolism.

[10]  M. Arosio,et al.  Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. , 1990, The Journal of clinical endocrinology and metabolism.

[11]  A. Harris,et al.  Long Term Effect of Incremental Doses of the Somatostatin Analog SMS 201–995 in 58 Acromegalic Patients* , 1990 .

[12]  J. Reubi,et al.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. , 1989, The Journal of clinical endocrinology and metabolism.

[13]  S. Lamberts,et al.  SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. , 1987, The Journal of clinical endocrinology and metabolism.

[14]  I. Jackson,et al.  Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). , 1986, Annals of internal medicine.

[15]  H. Nawata,et al.  Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. , 1986, The Journal of clinical endocrinology and metabolism.

[16]  I. Lancranjan,et al.  Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients , 2004, Pituitary.

[17]  I. Lancranjan,et al.  Sandostatin LAR in acromegalic patients: long-term treatment. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  P. Caron,et al.  Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. , 1997, The Journal of clinical endocrinology and metabolism.

[19]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[20]  C. Beaudoin,et al.  [Influence of dose and modalities of administration of BIM 23014 on growth hormone secretion in patients with acromegaly]. , 1992, Annales d'endocrinologie.

[21]  A. Harris,et al.  Long-Term Efficacy of Sandostatin®(SMS 201–995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group , 1988 .